



BIOGRAPHICAL SKETCH

Provide the following information for the Senior/key personnel and other significant contributors.

Follow this format for each person. **DO NOT EXCEED FIVE PAGES.**

NAME: Brandi, Maria Luisa

eRA COMMONS USER NAME (credential, e.g., agency login): marialuisa.brandi

POSITION TITLE: Full Professor of Endocrinology

EDUCATION/TRAINING

INSTITUTION AND LOCATION	DEGREE (if applicable)	Completion Date MM/YYYY	FIELD OF STUDY
Classical Lyceum, Orvieto, Italy	Licenza Liceale	06/1972	Classic Studies
University of Florence, Italy	MD	07/1977	Medicine/Surgery, 1 st Class Honors
University of Florence, Italy	Specialty	07/1980	Endocrinology, 1 st Class Honors
National Institutes of Health (NIH), USA	NIH Training	1984/1988	Endocrinology
University of Rome, Italy	Ph.D	10/1988	Cell Biology

A. Personal Statement

I made a series of key contributions in the fields of molecular and cellular endocrinology and of bone diseases that have had major impact on the taxonomy, diagnosis and clinical management of bone and mineral disorders. I developed over 10 permanent cell lines that made possible the understanding of key mechanisms of action for calci-phospho-tropic hormones. I developed in the early years genetic tests that made possible the translation of molecular discoveries into clinical practice. I established a solid group of research in Florence, Italy, where we span from basic science to clinical studies on bone and mineral disorders. Clinical Studies from Phase 1 to observational analyses have been carried out in Florence in the past three decades. We serve as reference Center in Italy for patients suffering for common and rare disorders of the parathyroid glands, with a great interest on hereditary endocrine tumors. I have initiated and maintain clinical databases and a biological repository of Multiple Endocrine Neoplasia Syndrome Type 1 (MEN1). In the past decade our interest was extended to rare metabolic bone disorders in the adult and soon we became a leading Center for the diagnosis and therapy of these difficult diseases. This prompted the development of international registries, whose we are active participants, sitting also in the steering committee of three different repositories. These contributions have facilitated the development of clinical guidelines, encompassing MEN 1, hyperparathyroidism, hypoparathyroidism, osteoporosis, and phosphate wasting disorders.

B. Positions and Honors

Positions and Employment

- 1999-present Full Professor of Endocrinology at the University of Florence and Director of the Complex Clinical Unit on Bone and Mineral Disorders at the Careggi Hospital, Florence, Italy
- 1990-present Director of the Regional Referral Center for Hereditary Endocrine Tumors, Careggi Hospital, Florence, Italy
- 1988-1999 Associate Professor of Endocrinology at the University of Florence, Florence, Italy
- 1984-1988 Visiting Associate at the Metabolic Diseases Branch, NIH, Bethesda, MD, USA
- 1986-1988 PhD Program at the University of Rome, Italy
- 1977-1980 Clinical Training Fellow at the University of Florence, Florence, Italy
- 1980-1984 Clinical Scientist at the University of Florence, Florence, Italy

Other Experience and Professional Memberships

University of Florence

- 1998-present Member of PhD Evaluation Boards
- 2000-2003 Representative functions for USA Academic Institutions
- 2004-2014 Coordinator of the Master on Metabolic Bone Diseases: From the Gene to the Cure
- 2004-2010 Scientific Director of the DeGene Spin-off
- 2007-2010 Delegate of the Rector for Italy/USA Academic Interactions
- 2016-present Delegate of the Rector for Health Education in the City of Florence

National, Italy

- 1990-present Director of the Regional Center on Hereditary Endocrine tumors
- 1991-present Coordinator of the Italian Group of Study on Multiple Endocrine Neoplasia Type 1
- 1996-1999 Chairman of the Italian Group of Study on Hypoparathyroidism
- 1997-1999 Member of the Scientific Committee of the Italian Society of Endocrinology
- 2001 President of the First International Workshop on the Genetics of Bone Diseases, Florence
- 2002-present Member of the Scientific Committee of the AILA Foundation
- 2002-present Member of the Scientific Committee of the InChianti Project
- 2008-present Consultant for the Tuscany Region on Osteoporosis
- 2004-present Reviser for Continuous Education in Medicine
- 2005 Member of the Working Group on Endocrine Disruptors, Italian Ministry of Health
- 2005-2007 President of the Italian Society on Osteoporosis (SIOMMMS)
- 2007-present Member of the Commission on Osteoporosis of the Italian Society on Orthopaedic (SIOT)
- 2009-2010 Member of the Steering Committee for the Position Paper of the Italian Ministry of Health on Osteoporosis
- 2010-present Executive Director of the OrtoMed Society
- 2015-present Scientific Attaché for the City of Florence
- 2017-2018 Member of the Steering Committee for the Position Paper of the Italian Ministry of Health on Osteoporosis
- 2019-present Coordinator of the Commission on Fragility Fractures of the Tuscany Region
- 2019-present President of the Italian FRAME Project for the secondary prevention of fragility fractures
- 2019-present Scientific Director of the Stabilimento Chimico Farmaceutico Militare of Italy

International

- 1984-1990 Reader in Endocrinology, Georgetown and Charlottesville University Schools of Medicine, USA
- 1988-1993 Member Board of Directors of the International Conferences on Calcium Regulating Hormones (ICCRH)
- 1990-1994 Member of the Editorial Board of Journal of Endocrinological Investigations
- 1990-1998 Member of the Editorial Board of Diabetes, Nutrition and Metabolism
- 1991 Chairman of the First International Conference on Hereditary Endocrine tumors, Florence, Italy
- 1991 President of the First International Conference on Steroids and Bone, Florence, Italy
- 1993-1994 Visiting Scientist at the William Harvey Research Institute, London, UK

- 1994 Member of the Scientific Committee of the IIIrd European Congress of Endocrinology, Amsterdam, The Netherlands
- 1995 President of the First International Meeting on New Developments in Nitric Oxide, Orvieto, Italy
- 1995 Member of the Scientific Committee of the Steroids and Bone ICCRH Satellite Meeting, Melbourne, Australia
- 1995-1998 President of the European Association for Women's Health
- 1996 UICC Fellow, NIDDK, NIH, Bethesda, MD, USA
- 1997 Recipient of an International Cancer Technology Transfer Fellowship, NIH, Bethesda, MD, USA
- 1997 Member of the International Advisory Board of the 3rd International Symposium on Women's Health and Menopause, Washington DC, USA
- 1997 President of the Second International Conference on Steroids and Bone, Siena, Italy
- 1998 UICC Fellow, NIDDK, NIH, Bethesda, MD, USA
- 1998 Member of the Scientific Committee of the VIIth European Congress of Endocrinology
- 1999-present Member of the Committee of the Scientific Advisors of the International Osteoporosis Foundation
- 1999-present Member of the International Multiple Endocrine Neoplasia Committee
- 2001 UICC Fellow, Mount Sinai Medical Center, New York, NY, USA
- 2002-present Member of the Editorial Board of Expert Opinion in Investigational Drugs
- 2002-present Scientific Director of the Italian Association on Multiple Endocrine Neoplasia (AIMEN)
- 2004-2007 Member of the Editorial Board of Endocrinology
- 2004-2008 Member of the Editorial Board of Journal of Bone and Mineral Research
- 2004-2019 Editor-in Chief of Clinical Cases in Mineral and Bone Metabolism
- 2008-present General Secretary of the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO)
- 2013 Chairman of the 4th International workshop on the Management of Asymptomatic Primary Hyperparathyroidism, Florence, Italy
- 2013-present Member of the Editorial Board of Calcified Tissue International
- 2015-present Member of the Board of the International Osteoporosis Foundation (IOF)
- 2015 Chairman of the First International Consensus Conference on Hypoparathyroidism, Florence, Italy
- 2016-present Member Steering Committee of the European Reference Centers Network on Rare Bone Diseases
- 2017-present Scientific Director of the Italian Association for Patients with Hypoparathyroidism (APPI)
- 2017 Chairman of the Third International Symposium on the Calcium Sensing Receptor, Florence, Italy
- 2019-present Scientific Director of the Italian Association on Phosphate Metabolic Disorders (AIFOSF)
- 2019-present Scientific Director of the Italian Association on Hypophosphatasia (API)
- 2019-present Member of the Editorial Board of Journal of the Endocrine Society
- 2019-present Editor in Endocrinology of Orphanet Journal
- 2019 Chairman of the First International Conference on Biomineralization in Health and Disease: From the Ocean to the Stars to the Land, Florence, Italy

Honors

- 1988 Roussel Italia Award
- 1989 The European Foundation Award
- 1990 The Shering Award of the Italian Society of Endocrinology
- 1991 The Sandoz Award for Gerontological Research
- 1998 The Helena Rubinstein Award "Women in Science"
- 2003 The Senior Award of the Italian Society of Endocrinology
- 2004 The International AILA Award
- 2013 The Pierre Delams IOF/ESCEO Prize
- 2016 The Top Italian Scientist Award
- 2016 The "Pinocchio di Carlo Lorenzini Grillo Parlante" Award
- 2019 The 9th world most cited author in the field of osteoporosis

C. Contributions to Science

My research has resulted in the production of novel cell models in cell biology, today available to several Laboratories around the world, and through these to the elucidation of basic mechanisms that control the bone and mineral metabolism. Treasuring my clinical experience I promoted the preparation of clinical guidelines in the area of bone and mineral metabolism, today used by clinicians worldwide (selected list of publications from a total of 770 peer-reviewed original research articles):

- Toccafondi R.S., Brandi M.L., Melander A. *Vasoactive intestinal peptide stimulation of human thyroid cell function.* J Clin Endocrinol Metab 58: 157-160, 1984.
- Brandi M.L., Fitzpatrick L.A., Fedak S., Aurbach G.D., Coon H.G. *Differentiated bovine parathyroid cells cultured for more than 140 population doublings show both parathyroid hormone synthesis and growth regulation by calcium ion concentration.* Prog Clin Biol Res 226: 265-275, 1986.
- Brandi M.L., Fitzpatrick L.A., Coon H.G., Aurbach G.D. *Bovine parathyroid cells: cultures maintained for more than 140 population doublings.* Proc Natl Acad Sci USA 83: 1709-1713, 1986.
- Brandi M.L., Aurbach G.D., Fitzpatrick L.A., Quarto R., Spiegel A.M., Blizotes M.M., Norton J.A., Doppman J.L., Marx S.J. *Parathyroid mitogenic activity in plasma from patients with multiple endocrine neoplasia type 1.* N Engl J Med 314: 1287-1293, 1986.
- Brandi M.L., Rotella C.M., Kohn L.D., Toccafondi R. *Unusual antagonistic actions of mixtures of vasoactive intestinal peptide, thyroid-stimulating antibodies, and cholera toxin on adenosine 3',5'-monophosphate accumulation in normal human thyroid cell cultures.* J Clin Endocrinol Metab 62: 1199-1205, 1986.
- Brandi M.L., Aurbach G.D., Fattorossi A., Quarto R., Marx S.J., Fitzpatrick L.A. *Antibodies cytotoxic to bovine parathyroid cells in autoimmune hypoparathyroidism.* Proc Natl Acad Sci USA 83: 8366-8369, 1986.
- Sakaguchi K., Santora A., Zimering M., Curcio F., Aurbach G.D., Brandi M.L. *Functional epithelial cell line cloned from rat parathyroid glands.* Proc Natl Acad Sci USA 84: 3269-3273, 1987.
- Brandi M.L., Marx S.J., Aurbach G.D., Fitzpatrick L.A. *Familial multiple endocrine neoplasia type 1: a new look at pathophysiology.* Endocr Rev 8: 391-405, 1987.
- Fattorossi A., Aurbach G.D., Sakaguchi K., Cama A., Marx S.J., Streeten E.A., Fitzpatrick L.A., Brandi M.L. *Anti-endothelial cell antibodies: detection and characterization in sera from patients with autoimmune hypoparathyroidism.* Proc Nat Acad Sci USA 85: 4015-4019, 1988.
- Marx S.J., Sakaguchi K, Green J. 3rd, Aurbach G.D., Brandi M.L. *Mitogenic activity on parathyroid cells in plasma from members of a large kindred with multiple endocrine neoplasia type 1.* J Clin Endocrinol Metab 67: 149-153, 1988.
- Streeten E.A., Ornberg R., Curcio F., Sakaguchi K., Marx S.J., Aurbach G.D., Brandi M.L. *Cloned endothelial cells from fetal bovine bone.* Proc Natl Acad Sci USA 86: 916-920, 1989.
- Coon H.G., Curcio F., Sakaguchi K., Brandi M.L., Swerdlow R.D. *Cell cultures of neuroblasts from rat olfactory epithelium that show odorant responses.* Proc Natl Acad Sci USA 86: 1703-1707, 1989.
- Ikeda K., Weir E.C, Sakaguchi K., Burtis W.J., Zimering M., Mangin M., Dreyer B.E., Brandi M.L., Aurbach G.D., Broadus A. *Clonal rat parathyroid cell line expresses a parathyroid hormone-related peptide but not parathyroid hormone itself.* Biochem Biophys Res Commun 162: 108-115, 1989.
- Zimering M.B., Brandi M.L., deGrange D.A., Marx S.J., Streeten E., Katsumata N., Murphy P.R., Sato Y., Friesen H.G., Aurbach G.D. *Circulating fibroblast growth factor-like substance in familial multiple endocrine neoplasia type 1.* J Clin Endocrinol Metab 70: 149-154, 1990.
- Sakaguchi K., Ikeda K., Curcio F., Aurbach G., Brandi M.L. *Subclones of a rat parathyroid cell line (PT-r): regulation of growth and production of parathyroid hormone-related peptide (PTHrP).* J Bone Miner Res 5: 863-869, 1990.
- Streeten E.A., Brandi M.L. *Biology of bone endothelial cells.* Bone Miner 10: 85-94, 1990.
- Gattei V., Bernabei P.A., Pinto A., Bezzini R., Ringressi A., Formigli L., Tanini A., Attadia V., Brandi M.L. *Phorbol ester induced osteoclast-like differentiation of a novel human leukemic cell line (FLG 29.1).* J Cell Biol 116: 437-447, 1992.
- Falchetti A., Bale A.E., Amorosi A., Bordi C., Cicchi P., Bandini S., Marx S.J., Brandi M.L. *Progression of uremic hyperparathyroidism involves allelic loss on chromosome 11.* J Clin Endocrinol Metab 76: 139-144, 1993.
- Zimering M.B., Katsumata N., Sato Y., Brandi M.L., Aurbach G.D., Marx S.J., Friesen H.G. *Increased basic fibroblast growth factor in plasma from multiple endocrine neoplasia type 1: relation to pituitary tumor.* J Clin Endocrinol Metab 76: 1182-1187, 1993.
- Brandi M.L., Weber G., Svensson A., Falchetti A., Tonelli F., Castello R., Furlani L., Scappaticci S., Fraccaro M., Larsson C. *Homozygotes for the autosomal dominant neoplasia syndrome (MEN 1).* Am J Hum Genet 53: 1167-1172, 1993.
- Bordi C., Falchetti A., Buffa R., Azzoni C., D'Adda T., Caruana P., Rindi G., Brandi M.L. *Production of basic fibroblast growth factor by gastric carcinoid tumors and their putative cells of origin.* Hum Pathol 25: 175-180, 1994.
- Brandi M.L., Bianchi M.L., Eisman J.A., Glorieux F., Adami S., Fiore C. E., Nuti R., Ortolani S. *Genetics of Osteoporosis.* Calcif Tissue Int 55: 161-163, 1994.
- Bianchi S., Fabiani S., Muratori M., Arnold A., Sakaguchi K., Miki T., Brandi M.L. *Calcium modulates the cyclin D1 expression in a rat parathyroid cell line.* Biochem Biophys Res Commun 204: 691-700, 1994.

- Bordi C., Falchetti A., Azzoni C., D'Adda T., Morelli A., Peracchia A., Brandi M.L. *Lack of allelic loss at the multiple endocrine neoplasia type 1 (MEN-1) gene locus in a pancreatic ductal (non-endocrine) adenocarcinoma of a patient with the MEN-1 syndrome.* Virchows Arch 426: 203-208, 1995.
- Formigli L., Orlandini S.Z., Benvenuti S., Masi L., Pinto A., Gattei V., Bernabei P.A., Robey P.G., Collin-Osdoby P., Brandi M.L. *In vitro structural and functional relationship between preosteoclastic and bone endothelial cells: a juxtacrine model for migration and adhesion of osteoclast precursors.* J Cell Physiol 162: 199-212, 1995.
- Brandi M.L., Hukkanen M., Umeda T., Moradi-Bihendi N., Bianchi S., Gross S.S., Polak J.M., MacIntyre I. *Bidirectional regulation of osteoclast function by nitric oxide synthase isoforms.* Proc Natl Acad Sci USA 92: 2954-2958, 1995.
- Fiorelli G., Gori F., Petilli M., Tanini A., Benvenuti S., Serio M., Bernabei P., Brandi M.L. *Functional estrogen receptors in a human preosteoclastic cell line.* Proc Natl Acad Sci USA 92: 2672-2676, 1995.
- Benvenuti S., Masi L., Falchetti A., Mancini L., Formigli L., Zecchi S., Amorosi A., Tonelli F., Brandi M.L. *HPE cells: a clonal endothelial cell line established from human parathyroid tissue (human parathyroid cell line).* Endothelium 5: 37-49, 1997.
- Falchetti A., Morelli A., Amorosi A., Tonelli F., Fabiani S., Martinetti V., Castello R., Furlani L., Brandi M.L. *Allelic Loss in parathyroid tumors from individuals homozygous for multiple endocrine neoplasia type 1.* J Clin Endocrinol Metab 82: 2278-2282, 1997.
- Gennari L., Becherini L., Masi L., Mansani R., Gonnelli S., Cepollaro C., Martini S., Montagnani A., Lentini G., Becorpi A.M., Brandi M.L. *Vitamin D and estrogen receptor allelic variants in Italian postmenopausal women: evidence of multiple gene contribution on bone mineral density.* J Clin Endocrinol Metab 83: 939-944, 1998.
- Gennari L., Becherini L., Mansani R., Masi L., Falchetti A., Morelli A., Colli E., Gonnelli S., Cepollaro C., Brandi M.L. *FOK I Polymorphism at translation initiation site of the vitamin D receptor gene predicts bone mineral density and vertebral fractures in postmenopausal Italian women.* J Bone Miner Res 14: 1379-1386, 1999.
- Falchetti A., Becherini L., Martinetti V., Morelli A., Benvenuti S., Picariello L., Gennari L., Lampugnani R., Bordi, Brandi M.L. *Telomerase repeat amplification protocol (TRAP): A new molecular marker for parathyroid carcinoma.* Biochem Biophys Res Commun 265: 252-255, 1999.
- Becherini L., Gennari L., Masi L., Mansani R., Massart F., Morelli A., Falchetti A., Gonnelli S., Fiorelli G., Tanini A., Brandi M.L. *Evidence of a linkage disequilibrium between polymorphisms in the human estrogen receptor alpha gene and their relationship to bone mass variation in postmenopausal Italian women.* Hum Mol Genet 9: 2043-2050, 2000.
- Picariello L., Benvenuti S., Recenti R., Formigli L., Falchetti A., Morelli A., Masi L., Tonelli F., Cicchi P., Brandi M.L. *Microencapsulation of human parathyroid cells: an "in vitro" study.* J Surg Res 96: 81-89, 2001.
- Masi L., Becherini L., Gennari L., Amedei A., Colli E., Falchetti A., Farci M., Silvestri S., Gonnelli S., Brandi M.L. *Polymorphism of the aromatase gene in postmenopausal Italian women: distribution and correlation with bone mass and fracture risk.* J Clin Endocrinol Metab 86: 2263-2269, 2001.
- Brandi M.L., Gagel R.F., Angeli A., Bilezikian J.P., Beck-Peccoz P., Bordi C., Conte-Devolx B., Falchetti A., Gheri R.G., Libroia A., Lips C.J.M., Lombardi G., Mannelli M., Pacini F., Ponder B.A., Raue F., Skogseid B., Tamburrano G., Thakker R.V., Thompson N.W., Tommasetti P., Tonelli F., Wells S.A. Jr., Marx S.J. *Guidelines for Diagnosis and Therapy of MEN Type 1 and Type 2.* J Clin Endocrinol Metab 86: 5658-5671, 2001.
- Vezzoli G., Tanini A., Ferrucci L., Soldati L., Bianchin C., Franceschelli F., Malentacchi C., Porfirio B., Adamo D., Terranegra A., Falchetti A., Cusi D., Bianchi G., Brandi M.L. *Influence of calcium-sensing receptor gene on urinary calcium excretion in stone-forming patients.* J Am Soc Nephrol 13: 2517-2523, 2002.
- Ioannidis J.P., Stavrou I., Trikalinos T.A., Zois C., Brandi M.L., Gennari L., Albagha O., Ralston S.H., Tsatsoulis A., *ER-alpha Genetics Meta-Analysis Association of polymorphisms of the estrogen receptor alpha gene with bone mineral density and fracture risk in women: a meta-analysis.* J Bone Miner Res 17: 2048-2060, 2002.
- Khosla S., Riggs B.L., Atkinson E.J., Oberg A.L., Mavilia C., Del Monte F., Melton L.J. 3rd, Brandi M.L. *Relationship of estrogen receptor genotypes to bone mineral density and to rates of bone loss in men.* J Clin Endocrinol Metab 89: 1808-1816, 2004.
- Gennari L., Masi L., Merlotti D., Picariello L., Falchetti A., Tanini A., Mavilia C., Del Monte F., Gonnelli S., Lucani B., Gennari C., Brandi M.L. *A polymorphic CYP19 TTTA repeat influences aromatase activity and estrogen levels in elderly men: effects on bone metabolism.* J Clin Endocrinol Metab 89: 2803-2810, 2004.
- Martinetti V., Picariello L., Tognarini I., Carbonell Sala S., Gozzini A., Azzari C., Mavilia C., Tanini A., Falchetti A., Fiorelli G., Tonelli F., Brandi M.L. *Erβ is a potent inhibitor of cell proliferation in the HCT8 human colon cancer cell line through regulation of cell cycle components.* Endocr Relat Cancer 12: 455-469, 2005.
- Falchetti A., Di Stefano M., Marini F., Del Monte F., Gozzini A., Masi L., Tanini A., Amedei A., Carossino A., Isaia G., Brandi M.L. *Segregation of a M404V mutation of the p62/sequestosome 1 (p62/SQSTM1) gene with polyostotic Paget's disease of bone in an Italian family.* Arthritis Res Ther 7: R1289-1295, 2005.
- Brandi M.L., Collin-Osdoby P. *Vascular biology and the skeleton.* J Bone Miner Res 21:183-192, 2006.
- Brandi M.L., Falchetti A. *What Is The Relationship Between Paget's Disease of Bone and Hyperparathyroidism.* J Bone Miner Res 21: 69-74, 2006.
- Tognarini I., Sorace S., Zonefrati R., Galli G., Gozzini A., Carbonell Sala S., Thyron G.D., Carossino A.M., Tanini A., Mavilia C., Azzari C., Sbaiz F., Facchini A., Capanna R., Brandi M.L. *In vitro differentiation of human mesenchymal stem cells on Ti6Al4V surfaces.* Biomaterials. 29(7):809-24, 2008 Epub 2007 Nov 26.
- Van Meurs J.B., Trikalinos T.A., Ralston S.H., Balcells S., Brandi M.L., Brixen K., Kiel D.P., Langdahl B.L., Lips P., Ljunggren O., Lorenc R., Obermayer-Pietsch B., Ohlsson C., Pettersson U., Reid D.M., Rousseau F., Scollen S., Van Hul W., Agueda L., Akesson

- K., Benevolenskaya L.I., Ferrari S.L., Hallmans G., Hofman A., Husted L.B., Kruk M., Kaptoge S., Karasik D., Karlsson M.K., Lorentzon M., Masi L., McGuigan F.E., Mellström D., Mosekilde L., Nogues X., Pols H.A., Reeve J., Renner W., Rivadeneira F., van Schoor N.M., Weber K., Ioannidis J.P., Uitterlinden A.G.; GENOMOS Study. *Large-scale analysis of association between LRP5 and LRP6 variants and osteoporosis*. JAMA. 19;299(11):1277-90, 2008.
- Falchetti A., Cilotti A., Vagelli L., Masi L., Amedei A., Cioppi F., Tonelli F., Brandi M.L. *A patient with MEN1-associated hyperparathyroidism, responsive to cinacalcet*. Nat Clin Pract Endocrinol Metab. 2008 Jun;4(6):351-7. Epub 2008.
 - Massart F., Marcucci G. Brandi M.L.. *Pharmacogenetics of bone treatments: the VDR and ERalpha gene story*. Pharmacogenomics 9(6):733-46, 2008. Review.
 - Eastell R., Arnold A., Brandi M.L., Brown E.M., D'Amour P., Hanley D.A., Rao D.S., Rubin M.R., Goltzman D., Silverberg S.J., Marx S.J., Peacock M., Mosekilde L., Bouillon R., Lewiecki E.M.. *Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop*. J Clin Endocrinol Metab. 94(2):340-50, 2009.
 - Falchetti A., Brandi M.L. *Multiple endocrine neoplasia type I variants and phenocopies: more than a nosological issue?* J Clin Endocrinol Metab. 94(5):1518-20, 2009.
 - Luzi E, Marini F, Tognarini I, Carbonelli Sala S, Galli G, Falchetti A, Brandi ML, *Ribozyme-mediated compensatory induction of menin-oncosuppressor function in primary fibroblasts from MEN1 patients*, Cancer Gene Ther. 17(11):814-25, 2010.
 - Luzi E, Brandi ML. *ARE microRNAs Involved in the Endocrine-Specific Pattern of Men1 Tumorigenesis??* Endocr Pract. 2011 Jul-Aug;17 Suppl 3:58-63.
 - Saggini A, Brandi ML. *Skin Lesions in Hereditary Endocrine Tumor Syndromes*. Endocr Pract. 2011 Jul17 Suppl 3:47-57.
 - Albagha OM, Wani SE, Visconti MR, Alonso N, Goodman K, Brandi ML, Cundy T, Chung PY, Dargie R, Devogelaer JP, Falchetti A, Fraser WD, Gennari L, Gianfrancesco F, Hooper MJ, Van Hul W, Isaia G, Nicholson GC, Nuti R, Papapoulos S, Montes Jdel P, Ratajczak T, Rea SL, Rendina D, Gonzalez-Sarmiento R, Di Stefano M, Ward LC, Walsh JP, Ralston SH; Genetic Determinants of Paget's Disease (GDPD) Consortium. *Genome-wide association identifies three new susceptibility loci for Paget's disease of bone*. Nat Genet. 2011 May 29;43(7):685-9.
 - Bilezikian JP, Khan A, Potts JT Jr, Brandi ML, Clarke BL, Shoback D, Jüppner H, D'Amour P, Fox J, Rejnmark L, Mosekilde L, Rubin MR, Dempster D, Gafni R, Collins MT, Sliney J, Sanders J. *Hypoparathyroidism in the adult: Epidemiology, diagnosis, pathophysiology, target-organ involvement, treatment, and challenges for future research*. J Bone Miner Res. 2011 Oct;26(10):2317-37.
 - Papapoulos S, Chapurlat R, Libanati C, Brandi M, Brown J, Czerwiński E, Krieg MA, Man Z, Mellström D, Radominski S, Reginster JY, Resch H, Román J, Roux C, Vittinghoff E, Austin M, Daizadeh N, Bradley M, Grauer A, Cummings S, Bone H. *Five years of denosumab exposure in women with postmenopausal osteoporosis: Results from the first two years of the FREEDOM extension*. J Bone Miner Res. 27(3):694-701, 2012.
 - Jensen RT, Cadiot G, Brandi ML, de Herder WW, Kaltsas G, Komminoth P, Scoazec JY, Salazar R, Sauvanet A, Kianmanesh R. *ENETS Consensus Guidelines for the Management of Patients with Digestive Neuroendocrine Neoplasms: Functional Pancreatic Endocrine Tumor Syndromes*. Neuroendocrinology. 95(2):98-119, 2012.
 - Rizzoli R, Body JJ, De Censi A, Reginster JY, Piscitelli P, Brandi ML; on behalf of the European Society for Clinical and Economical aspects of Osteoporosis and Osteoarthritis (ESCEO). *Guidance for the prevention of bone loss and fractures in postmenopausal women treated with aromatase inhibitors for breast cancer: an ESCEO position paper*. Osteoporos Int. 23(11):2567-76, 2012.
 - Falchetti A, Gozzini A, Terranegra A, Soldati L, Vezzoli G, Leoncini G, Giusti F, Franceschelli F, Masi L, Tanini A, Cavalli L, Brandi ML. *A novel germline inactivating mutation in the CASR gene in an Italian kindred affected by familial hypocalciuric hypercalcemia* Eur J Endocrinol. 166(5):933-40, 2012.
 - Luzi E, Marini F, Tognarini I, Galli G, Falchetti A, Brandi ML. *The Regulatory Network Menin-MicroRNA 26a As a Possible Target for RNA-Based Therapy of Bone Diseases*. Nucleic Acid Ther. 22(2):103-8, 2012.
 - Estrada K, Styrkarsdóttir U, Evangelou E, Hsu YH, Duncan EL, Ntzani EE, Oei L, Albagha OM, Amin N, Kemp JP, Koller DL, Li G, Liu CT, Minster RL, Moayyeri A, Vandenput L, Willner D, Xiao SM, Yerges-Armstrong LM, Zheng HF, Alonso N, Eriksson J, Kammerer CM, Kaptoge SK, Leo PJ, Thorleifsson G, Wilson SG, Wilson JF, Aalto V, Alen M, Aragaki AK, Aspelund T, Center JR, Dailiana Z, Duggan DJ, Garcia M, Garcia-Giralt N, Giroux S, Hallmans G, Hocking LJ, Husted LB, Jameson KA, Khusainova R, Kim GS, Kooperberg C, Koromila T, Kruk M, Laaksonen M, Lacroix AZ, Lee SH, Leung PC, Lewis JR, Masi L, Mencej-Bedrac S, Nguyen TV, Nogues X, Patel MS, Prezelj J, Rose LM, Scollen S, Siggeirsdóttir K, Smith AV, Svensson O, Trompet S, Trummer O, van Schoor NM, Woo J, Zhu K, Balcells S, Brandi ML, Buckley BM, Cheng S, Christiansen C, Cooper C, Dedoussis G, Ford I, Frost M, Goltzman D, González-Macías J, Kähönen M, Karlsson M, Khusnutdinova E, Koh JM, Kollia P, Langdahl BL, Leslie WD, Lips P, Ljunggren O, Lorenc RS, Marc J, Mellström D, Obermayer-Pietsch B, Olmos JM, Pettersson-Kymmer U, Reid DM, Riancho JA, Ridker PM, Rousseau F, Lagboom PE, Tang NL, Urreizti R, Van Hul W, Viikari J, Zarrabeitia MT, Aulchenko YS, Castano-Betancourt M, Grundberg E, Herrera L, Ingvarsson T, Johannsdóttir H, Kwan T, Li R, Luben R, Medina-Gómez C, Th Palsson S, Reppe S, Rotter JI, Sigurdsson G, van Meurs JB, Verlaan D, Williams FM, Wood AR, Zhou Y, Gautvik KM, Pastinen T, Raychaudhuri S, Cauley JA, Chasman DI, Clark GR, Cummings SR, Danoy P, Dennison EM, Eastell R, Eisman JA, Gudnason V, Hofman A, Jackson RD, Jones G, Jukema JW, Khaw KT, Lehtimäki T, Liu Y, Lorentzon M, McCloskey E, Mitchell BD, Nandakumar K, Nicholson GC, Oostra BA, Peacock M, Pols HA, Prince RL, Raitakari O, Reid IR, Robbins J, Sambrook PN, Sham PC, Shuldiner AR, Tylavsky FA, van Duijn CM, Wareham NJ, Cupples LA, Econs MJ, Evans DM, Harris TB, Kung AW, Psaty BM, Reeve J, Spector TD, Streeten EA, Zillikens MC, Thorsteinsdóttir U, Ohlsson C, Karasik D, Richards JB, Brown MA, Stefansson K, Uitterlinden AG, Ralston SH, Ioannidis JP, Kiel

DP, Rivadeneira F. *Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture*. Nat Genet. 44(5):491-501, 2012.

- Liu CT, Estrada K, Yerges-Armstrong LM, Amin N, Evangelou E, Li G, Minster RL, Carless MA, Kammerer CM, Oei L, Zhou Y, Alonso N, Dailiana Z, Eriksson J, García-Giralt N, Giroux S, Husted LB, Khusainova RI, Koromila T, Kung AW, Lewis JR, Masi L, Mencej-Bedrac S, Nogues X, Patel MS, Prezelj J, Richards JB, Sham PC, Spector T, Vandenput L, Xiao SM, Zheng HF, Zhu K, Balcells S, Brandi ML, Frost M, Goltzman D, González-Macías J, Karlsson M, Khusnutdinova EK, Kollia P, Langdahl BL, Ljunggren O, Lorentzon M, Marc J, Mellström D, Ohlsson C, Olmos JM, Ralston SH, Riancho JA, Rousseau F, Urreiziti R, Van Hul W, Zarrabeitia MT, Castano-Betancourt M, Demissie S, Grundberg E, Herrera L, Kwan T, Medina-Gómez C, Pastinen T, Sigurdsson G, Thorleifsson G, Vanmeurs JB, Blangero J, Hofman A, Liu Y, Mitchell BD, O'Connell JR, Oostra BA, Rotter JI, Stefansson K, Streeten EA, Styrkarsdottir U, Thorsteinsdottir U, Tylavsky FA, Uitterlinden A, Cauley JA, Harris TB, Ioannidis JP, Psaty BM, Robbins JA, Zillikens MC, Vanduijn CM, Prince RL, Karasik D, Rivadeneira F, Kiel DP, Cupples LA, Hsu YH. *Assessment of gene-by-sex interaction effect on bone mineral density*. J Bone Miner Res. 27(10):2051-64, 2012.
- Thakker RV, Newey PJ, Walls GV, Bilezikian J, Dralle H, Ebeling PR, Melmed S, Sakurai A, Tonelli F, Brandi ML. *Clinical Practice Guidelines for Multiple Endocrine Neoplasia Type 1 (MEN1)*. J Clin Endocrinol Metab. 97(9): 2990-3011, 2012.
- Luzi E, Marini F, Giusti F, Galli G, Cavalli L, Brandi ML. *The Negative Feedback-Loop between the Oncomir Mir-24-1 and Menin Modulates the Men1 Tumorigenesis by Mimicking the "Knudson's Second Hit"*. PLoS One. 7(6):e39767, 2012.
- Pampaloni B, Bartolini E, Barbieri M, Piscitelli P, Di Tanna GL, Giolli L, Brandi ML. *Validation of a Food-Frequency Questionnaire for the Assessment of Calcium Intake in Schoolchildren Aged 9-10 Years*. Calcif Tissue Int. 93(1):23-38, 2013.
- Rizzoli R, Reginster JY, Arnal JF, Bautmans I, Beaudart C, Bischoff-Ferrari H, Biver E, Boonen S, Brandi ML, Chines A, Cooper C, Epstein S, Fielding RA, Goodpaster B, Kanis JA, Kaufman JM, Laslop A, Malafarina V, Mañas LR, Mitlak BH, Oreffo RO, Petermans J, Reid K, Rolland Y, Sayer AA, Tsouderos Y, Visser M, Bruyère O. *Quality of life in sarcopenia and frailty*. Calcif Tissue Int. 93(2):101-20, 2013.
- Falcini F, Rigante D, Masi L, Covino M, Franceschelli F, Leoncini G, Tarantino G, Matucci Cerinic M, Brandi ML. *Fibroblast growth factor 23 (FGF23) gene polymorphism in children with Kawasaki syndrome (KS) and susceptibility to cardiac abnormalities*. Ital J Pediatr. 39(1):69, 2013.
- Mannstadt M, Clarke BL, Vokes T, Brandi ML, Ranganath L, Fraser WD, Lakatos P, Bajnok L, Garceau R, Mosekilde L, Lagast H, Shoback D, Bilezikian JP. *Efficacy and safety of recombinant human parathyroid hormone (1-84) in hypoparathyroidism (REPLACE): a double-blind, placebo-controlled, randomised, phase 3 study*. Lancet Diabetes Endocrinol. 2013 Dec;1(4):275-83. doi: 10.1016/S2213-8587(13)70106-2. Epub 2013 Oct 7. Erratum in: Lancet Diabetes Endocrinol. 2014 Jan;2(1):e3. Dosage error in article text.
- Fabbri S, Ciuffi S, Nardone V, Gomes AR, Mavilia C, Zonefrati R, Galli G, Luzi E, Tanini A, Brandi ML. *PTH-C1: a rat continuous cell line expressing the parathyroid phenotype*. Endocrine. 47(1): 90-9, 2014.
- Romagnoli C, Brandi ML. *Adipose mesenchymal stem cells in the field of bone tissue engineering*. World J Stem Cells. 6(2):144-52, 2014.
- Tonelli F, Giudici F, Giusti F, Marini F, Cianferotti L, Nesi G, Brandi ML. *A heterozygous frameshift mutation in exon 1 of CDKN1B gene in a patient affected by MEN4 syndrome*. Eur J Endocrinol. 171(2):K7-K17, 2014.
- Bilezikian JP, Brandi ML, Eastell R, Silverberg SJ, Udelsman R, Marcocci C, Potts JT Jr. *Guidelines for the Management of Asymptomatic Primary Hyperparathyroidism: Summary Statement from the Fourth International Workshop*. J Clin Endocrinol Metab. 99(10):3561-9, 2014.
- Eastell R, Brandi ML, Costa AG, D'Amour P, Shoback DM, Thakker RV. *Diagnosis of Asymptomatic Primary Hyperparathyroidism: Proceedings of the Fourth International Workshop*. J Clin Endocrinol Metab. 99(10): 3570-9, 2014.
- Kanis JA, McCloskey E, Branco J, Brandi ML, Dennison E, Devogelaer JP, Ferrari S, Kaufman JM, Papapoulos S, Reginster JY, Rizzoli R. *Goal-directed treatment of osteoporosis in Europe*. Osteoporos Int. 25(11):2533-43, 2014.
- Marcucci G, Zimran A, Bembi B, Kanis J, Reginster JY, Rizzoli R, Cooper C, Brandi ML. *Gaucher disease and bone manifestations*. Calcif Tissue Int. 95(6):477-94, 2014.
- Khan AA, Morrison A, Hanley DA, Felsenberg D, McCauley LK, O'Ryan F, Reid IR, Ruggiero SL, Taguchi A, Tetradis S, Watts NB, Brandi ML, Peters E, Guise T, Eastell R, Cheung AM, Morin SN, Masri B, Cooper C, Morgan SL, Obermayer-Pietsch B, Langdahl BL, Al Dabagh R, Davison KS, Kendler DL, Sándor GK, Josse RG, Bhandari M, El Rabbany M, Pierroz DD, Sulimani R, Saunders DP, Brown JP, Compston J; International Task Force on Osteonecrosis of the Jaw. *Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus*. J Bone Miner Res. 30(1):3-23, 2015.
- Masi L, Beltrami G, Ottanelli S, Franceschelli F, Gozzini A, Zonefrati R, Galli G, Ciuffi S, Mavilia C, Giusti F, Marcucci G, Cioppi F, Colli E, Fossi C, Franchi A, Casentini C, Capanna R, Brandi ML. *Human Preosteoblastic Cell Culture from a Patient with Severe Tumoral Calcinosis-Hyperphosphatemia Due to a New GALNT3 Gene Mutation: Study of In Vitro Mineralization*. Calcif Tissue Int. 96(5):438-52, 2015.
- Cianferotti L, Cricelli C, Kanis JA, Nuti R, Reginster JY, Ringe JD, Rizzoli R, Brandi ML. *The clinical use of vitamin D metabolites and their potential developments: a position statement from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the International Osteoporosis Foundation (IOF)*. Endocrine. 50(1): 12-26, 2015.
- Cianferotti L, Parri S, Gronchi G, Rizzuti C, Fossi C, Black DM, Brandi ML. *Changing patterns of prescription in vitamin D supplementation in adults: analysis of a regional dataset*. Osteoporos Int. 26(11): 2695-702, 2015.

- Masi L, Agnusdei D, Bilezikian J, Chappard D, Chapurlat R, Cianferotti L, Devogelaer JP, El Maghraoui A, Ferrari S, Javaid MK, Kaufman JM, Liberman UA, Lyritis G, Miller P, Napoli N, Roldan E, Papapoulos S, Watts NB, Brandi ML. *Taxonomy of rare genetic metabolic bone disorders*. *Osteoporos Int* 26(10): 2529-59, 2015.
- Cianferotti L, Gomes AR, Fabbri S, Tanini A, Brandi ML. *The calcium-sensing receptor in bone metabolism: from bench to bedside and back*. *Osteoporos Int*. 26(8):2055-71, 2015.
- Giusti F, Cianferotti L, Gronchi G, Cioppi F, Masi L, Faggiano A, Colao A, Ferolla P, Brandi ML. *Cinacalcet therapy in patients affected by primary hyperparathyroidism associated to Multiple Endocrine Neoplasia Syndrome type 1 (MEN1)*. *Endocrine*. 52(3): 495-506, 2016.
- Pampaloni B, Cianferotti L, Gronchi G, Bartolini E, Fabbri S, Tanini A, Brandi ML. *Growing Strong and Healthy with Mister Bone: An Educational Program to Have Strong Bones Later in Life*. *Nutrients*. 7(12):9985-98, 2015.
- Bilezikian JP, Brandi ML, Cusano NE, Mannstadt M, Rejnmark L, Rizzoli R, Rubin MR, Winer KK, Liberman UA, Potts JT Jr. *Management of Hypoparathyroidism: Present and Future*. *J Clin Endocrinol Metab*. 2016 Jun;101(6):2313-24. doi: 10.1210/jc.2015-3910. Epub 2016 Mar 3.
- Brandi ML, Bilezikian JP, Shoback D, Bouillon R, Clarke BL, Thakker RV, Khan AA, Potts JT Jr., *Management of Hypoparathyroidism: Summary Statement and Guidelines*. *J Clin Endocrinol Metab*. 2016 Jun;101(6):2273-83. doi: 10.1210/jc.2015-3907. Epub 2016 Mar 4.
- Luzi E, Marini F, Ciuffi S, Galli G, Brandi ML. *An autoregulatory network between menin and pri-miR-24-1 is required for the processing of its specific modulator miR-24-1 in BON1 cells*. *Mol Biosyst*. 2016 May 24;12(6):1922-8.
- Khan AA, Hanley DA, Rizzoli R, Bollerslev J, Young JE, Rejnmark L, Thakker R, D'Amour P, Paul T, Van Uum S, Shrayyef MZ, Goltzman D, Kaiser S, Cusano NE, Bouillon R, Mosekilde L, Kung AW, Rao SD, Bhadada SK, Clarke BL, Liu J, Duh Q, Lewiecki EM, Bandeira F, Eastell R, Marcocci C, Silverberg SJ, Udelsman R, Davison KS, Potts JT Jr, Brandi ML, Bilezikian JP. *Primary hyperparathyroidism: review and recommendations on evaluation, diagnosis, and management. A Canadian and international consensus*. *Osteoporos Int*. 28(1): 1-19, 2017.
- Khan AA, Morrison A, Kendler DL, Rizzoli R, Hanley DA, Felsenberg D, McCauley LK, O'Ryan F, Reid IR, Ruggiero SL, Taguchi A, Tetradis S, Watts NB, Brandi ML, Peters E, Guise T, Eastell R, Cheung AM, Morin SN, Masri B, Cooper C, Morgan SL, Obermayer-Pietsch B, Langdahl BL, Dabagh RA, Davison KS, Sándor GK, Josse RG, Bhandari M, El Rabbany M, Pierroz DD, Sulimani R, Saunders DP, Brown JP, Compston J; International Task Force on Osteonecrosis of the Jaw. *Case-Based Review of Osteonecrosis of the Jaw (ONJ) and Application of the International Recommendations for Management From the International Task Force on ONJ*. *J Clin Densitom*. 2017 Jan - Mar;20(1):8-24.
- Cipriani C, Pepe J, Biamonte F, Manai R, Biondi P, Nieddu L, Cianferotti L, Brandi ML, Minisola S. *The Epidemiology of Hypoparathyroidism in Italy: An 8-Year Register-Based Study*. *Calcif Tissue Int*. 2017 Mar;100(3):278-285.
- Giusti F, Cianferotti L, Boaretto F, Cetani F, Cioppi F, Colao A, Davi MV, Faggiano A, Fanciulli G, Ferolla P, Ferone D, Fossi C, Giudici F, Gronchi G, Loli P, Mantero F, Marcocci C, Marini F, Masi L, Opocher G, Beck-Peccoz P, Persani L, Scillitani A, Sciortino G, Spada A, Tomassetti P, Tonelli F, Brandi ML. *Multiple endocrine neoplasia syndrome type 1: institution, management, and data analysis of a nationwide multicenter patient database*. *Endocrine*. 58(2): 349-359. Lapi F, Bianchini E, Michieli R, Pasqua A, Cricelli I, Mazzaglia G, Frediani B, Prieto-Alhambra D, Brandi ML, Cricelli C. *Erratum to: Assessing risk of osteoporotic fractures in primary care: development and validation of the FRA-HS algorithm*. *Calcif Tissue Int*. 2017 Jun;100(6):550.
- Cianferotti L, Bertoldo F, Bischoff-Ferrari HA, Bruyere O, Cooper C, Cutolo M, Kanis JA, Kaufman JM, Reginster JY, Rizzoli R, Brandi ML. *Vitamin D supplementation in the prevention and management of major chronic diseases not related to mineral homeostasis in adults: research for evidence and a scientific statement from the European society for clinical and economic aspects of osteoporosis and osteoarthritis (ESCEO)*. *Endocrine*. 2017 May;56(2):245-261.
- Luzi E, Ciuffi S, Marini F, Mavilia C, Galli G, Brandi ML. *Analysis of differentially expressed microRNAs in MEN1 parathyroid adenomas*. *Am J Transl Res*. 2017 Apr 15;9(4):1743-1753.
- Vannucci L, Marini F, Giusti F, Ciuffi S, Tonelli F, Brandi ML. *MEN1 in children and adolescents: Data from patients of a regional referral center for hereditary endocrine tumors*. *Endocrine*. 59(2): 438-448, 2018.
- Bone HG, Wagman RB, Brandi ML, Brown JP, Chapurlat R, Cummings SR, Czerwiński E, Fahrleitner-Pammer A, Kendler DL, Lippuner K, Reginster JY, Roux C, Malouf J, Bradley MN, Daizadeh NS, Wang A, Dakin P, Pannacciulli N, Dempster DW, Papapoulos S. *10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension*. *Lancet Diabetes Endocrinol*. 2017 Jul;5(7):513-523.
- Minisola S, Cianferotti L, Biondi P, Cipriani C, Fossi C, Franceschelli F, Giusti F, Leoncini G, Pepe J, Bischoff-Ferrari HA, Brandi ML. *Correction of vitamin D status by calcidiol: pharmacokinetic profile, safety, and biochemical effects on bone and mineral metabolism of daily and weekly dosage regimens*. *Osteoporos Int*. 28(11): 3239-3249, 2017.
- Saag KG, Petersen J, Brandi ML, Karaplis AC, Lorentzon M, Thomas T, Maddox J, Fan M, Meisner PD, Grauer A. *Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis*. *N Engl J Med*. 2017 Oct 12;377(15):1417-1427.
- Marini F, Giusti F, Fossi C, Cioppi F, Cianferotti L, Masi L, Boaretto F, Zovato S, Cetani F, Colao A, Davi MV, Faggiano A, Fanciulli G, Ferolla P, Ferone D, Loli P, Mantero F, Marcocci C, Opocher G, Beck-Peccoz P, Persani L, Scillitani A, Guizzardi F, Spada A, Tomassetti P, Tonelli F, Brandi ML. *Multiple endocrine neoplasia type 1: analysis of germline MEN1 mutations in the Italian multicenter MEN1 patient database*. *Endocrine*. 62(1): 215-233, 2018.
- Marcucci G, Cianferotti L, Parri S, Altieri P, Arvat E, Benvenga S, Betterle C, Bondanelli M, Boscaro M, Camozzi V, Centaro GM, Cetani F, Chiodini I, Ciampolillo A, Colao A, Corbetta S, De Feo ML, Uberti ED, Faggiano A, Fornari R, Gaspari AL, Giorgino F,

- Giuliani V, Iacobone M, Innaro N, Lamacchia O, Lenzi A, Mantovani G, Marcocci C, Masi L, Migliaccio S, Palmieri S, Pasquali R, Perigli G, Piccini V, Romagnoli E, Ruggeri RM, Rulli F, Samà MT, Tomaino G, Trimarchi F, Zatelli MC, Brandi ML. *HypoparaNet: A Database of Chronic Hypoparathyroidism Based on Expert Medical-Surgical Centers in Italy*. *Calcif Tissue Int*. 103(2): 151-163, 2018.
- Cianferotti L, Parri S, Gronchi G, Marcucci G, Cipriani C, Pepe J, Raglianti M, Minisola S, Brandi ML. *Prevalence of Chronic Hypoparathyroidism in a Mediterranean Region as Estimated by the Analysis of Anonymous Healthcare Database*. *Calcif Tissue Int*. 103(2): 144-150, 2018.
 - Vellucci R, Terenzi R, Kanis JA, Kress HG, Mediati RD, Reginster JY, Rizzoli R, Brandi ML. *Understanding osteoporotic pain and its pharmacological treatment*. *Osteoporos Int*. 29(7): 1477-1491, 2018.
 - Marcucci G, Masi L, Ferrari S, Haffner D, Javaid MK, Kamenický P, Reginster JY, Rizzoli R, Brandi ML. *Phosphate wasting disorders in adults*. *Osteoporos Int*. 29(11):2369-2387, 2018.
 - Marangoni F, Pellegrino L, Verduci E, Ghiselli A, Bernabei R, Calvani R, Cetin I, Giampietro M, Perticone F, Piretta L, Giacco R, La Vecchia C, Brandi ML, Ballardini D, Banderali G, Bellentani S, Canzone G, Cricelli C, Faggiano P, Ferrara N, Flachi E, Gonnelli S, Macca C, Magni P, Marelli G, Marrocco W, Miniello VL, Origo C, Pietrantonio F, Silvestri P, Stella R, Strazzullo P, Troiano E, Poli A. *Cow's Milk Consumption and Health: A Health Professional's Guide*. *J Am Coll Nutr*. 38(3): 197-208, 2019.
 - Habibullah M, Porter JA, Kluger N, Ranki A, Krohn KJE, Brandi ML, Brown EM, Weetman AP, Kemp EH. *Calcium-Sensing Receptor Autoantibodies in Patients with Autoimmune Polyendocrine Syndrome Type 1: Epitopes, Specificity, Functional Affinity, IgG Subclass, and Effects on Receptor Activity*. *J Immunol*. 201(11): 3175-3183, 2018.
 - Marini F, Giusti F, Brandi ML. *Multiple endocrine neoplasia type 1: extensive analysis of a large database of Florentine patients*. *Orphanet J Rare Dis*. 14;13(1):205, 2018.
 - Hannan FM, Kallay E, Chang W, Brandi ML, Thakker RV. *The calcium-sensing receptor in physiology and in calcitropic and noncalcitropic diseases*. *Nat Rev Endocrinol*. 2018 Dec;15(1):33-51.
 - Khan AA, Koch C, Van Uum SHM, Baillargeon JP, Bollerslev J, Brandi ML, Marcocci C, Rejnmark L, Rizzoli R, Shrayyef MZ, Thakker RV, Yildiz BO, Clarke B. *Standards of Care for Hypoparathyroidism in Adults*. *Eur J Endocrinol*. 2018 Dec 1. pii: EJE-18-0609.R1.
 - Marcucci G, Brandi ML. *A New Era for Chronic Management of Hypoparathyroidism: Parathyroid Hormone Peptides*. *Front Horm Res*. 2019;51:165-171.
 - Marcucci G, Brandi ML. *Conventional Treatment of Hypoparathyroidism*. *Front Horm Res*. 2019;51:160-164.
 - Haffner D, Emma F, Eastwood DM, Duplan MB, Bacchetta J, Schnabel D, Wicart P, Bockenbauer D, Santos F, Levchenko E, Harvengt P, Kirchhoff M, Di Rocco F, Chaussain C, Brandi ML, Savendahl L, Briot K, Kamenický P, Rejnmark L, Linglart A. *Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia*. *Nat Rev Nephrol*. 2019 Jul;15(7):435-455.
 - Marcucci G, Beltrami G, Tamburini A, Body JJ, Confavreux CB, Hadji P, Holzer G, Kendler D, Napoli N, Pierroz DD, Rizzoli R, Brandi ML. *Bone health in childhood cancer: review of the literature and recommendations for the management of bone health in childhood cancer survivors*. *Ann Oncol*. 2019 May 21.
 - Portale AA, Carpenter TO, Brandi ML, Briot K, Cheong HI, Cohen-Solal M, Crowley R, Jan De Beur S, Eastell R, Imanishi Y, Imel EA, Ing S, Ito N, Javaid M, Kamenický P, Keen R, Kubota T, Lachmann R, Perwad F, Pitukcheewanont P, Ralston SH, Takeuchi Y, Tanaka H, Weber TJ, Yoo HW, Zhang L, Theodore-Oklota C, Mealiffe M, San Martin J, Insogna K. *Continued Beneficial Effects of Burosumab in Adults with X-Linked Hypophosphatemia: Results from a 24-Week Treatment Continuation Period After a 24-Week Double-Blind Placebo-Controlled Period*. *Calcif Tissue Int*. 2019 Sep;105(3):271-284.
 - Javaid MK, Boyce A, Appelman-Dijkstra N, Ong J, Defabianis P, Offiah A, Arundel P, Shaw N, Pos VD, Underhill A, Portero D, Heral L, Heegaard AM, Masi L, Monsell F, Stanton R, Dijkstra PDS, Brandi ML, Chapurlat R, Hamdy NAT, Collins MT. *Best practice management guidelines for fibrous dysplasia/McCune-Albright syndrome: a consensus statement from the FD/MAS international consortium*. *Orphanet J Rare Dis*. 2019 Jun 13;14(1):139.
 - Cronin O, Forsyth L, Goodman K, Lewis SC, Keerie C, Walker A, Porteous M, Cetnarskyj R, Ranganath LR, Selby PL, Hampson G, Chandra R, Ho S, Tobias JH, Young-Min S, McKenna MJ, Crowley RK, Fraser WD, Gennari L, Nuti R, Brandi ML, Del Pino-Montes J, Devogelaer JP, Durnez A, Isaia G, Di Stefano M, Guañabens N, Blanch J, Seibel MJ, Walsh JP, Kotowicz MA, Nicholson GC, Duncan EL, Major G, Horne A, Gilchrist NL, Boers M, Murray GD, Charnock K, Wilkinson D, Russell RGG, Ralston SH. *Zoledronate in the prevention of Paget's (ZiPP): protocol for a randomised trial of genetic testing and targeted zoledronic acid therapy to prevent SQSTM1-mediated Paget's disease of bone*. *BMJ Open*. 2019 Sep 4;9(9):e030689.
 - Donati S, Ciuffi S, Brandi ML. *Human Circulating miRNAs Real-time qRT-PCR-based Analysis: An Overview of Endogenous Reference Genes Used for Data Normalization*. *Int J Mol Sci*. 2019 Sep 5;20(18). pii: E4353.
 - Javaid MK, Boyce A, Appelman-Dijkstra N, Ong J, Defabianis P, Offiah A, Arundel P, Shaw N, Pos VD, Underhill A, Portero D, Heral L, Heegaard AM, Masi L, Monsell F, Stanton R, Dijkstra PDS, Brandi ML, Chapurlat R, Hamdy NAT, Collins MT. *Correction to: Best practice management guidelines for fibrous dysplasia/McCune-Albright syndrome: a consensus statement from the FD/MAS international consortium*. *Orphanet J Rare Dis*. 2019 Nov 21;14(1):267.
 - Lecoq AL, Brandi ML, Linglart A, Kamenický P. *Management of X-linked hypophosphatemia in adults*. *Metabolism*. 2020 Feb;103S:154049.

D. Additional Information: Research Support and No Profit Experience

Ongoing/Recent Research Support

Brandi (PI) 2011-2016

University of Edimburgh - Randomised trial on hereditary Paget disease of bone.

Brandi (PI) 2013-2016

EU - CREDITS4HEALTH - Credits-based, people-centric approach for the adoption of healthy life-styles and balanced Mediterranean diet in the frame of social participation and innovation for health promotion.

Brandi (PI) 2013-2016

Regione Toscana - MicroRNA codes in osteosarcoma cancer stem cells.

Brandi (PI) 2013-2015

Agenzia Italiana del Farmaco (AIFA) - Recombinant human parathyroid hormone (rhPTH (1-34): Teripatide) as therapy for refractory hypoparathyroidism code MRAR08E003.

Brandi (PI) 2014-2015

Bruno Farmaceutici - The effect of a daily and weekly administration of different doses of calcidiol on 25(OH)D₃ serum levels and on mineral and bone metabolic markers in postmenopausal female subjects and in male subjects, both over 55 years of age with inadequate levels or deficit of 25(OH)D₃.

Brandi (PI) 2014-2017

MIUR-PRIN – Skeletal Musclicrinology.

Brandi (PI) 2015-2017

Fondazione Cassa di Risparmio di Firenze - Next-generation sequencing in hereditary endocrine tumors.

Brandi (co-applicant) 2015-2020

EU - CaSR Biomedicine - Calcium-Sensing Receptor (CaSR): Therapeutics for Non-Communicable Diseases.

Brandi (PI) 2016-2017

Shire Italia – Bone metabolism in Gaucher disease.

Brandi (PI) 2016-2017

Ultragenyx Pharmaceutical - A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study with Open-Label Extension to Assess the Efficacy and Safety of KRN23 in Adults with X-linked Hypophosphatemia (XLH).

Brandi (PI) 2016-2017

Banca Ifigest (fondazione Biagioni-Borgogni ONLUS) - In vitro study of the role of APC gene mutations on osteoblastic differentiation and mineralisation in mesenchymal stem cells of patients with family adenomatosis polyposia.

Brandi (PI) 2016-2017

Banca d'Italia - In vitro study on the effects of parathyroid hormone (PTH) on bone mineralization process.

Brandi (PI) 2016-2020

MIUR-PRIN - Complex signatures of circulating miRNAs as novel biomarkers for osteoporosis and fracture risk.

Brandi (PI) 2016-2020

Alexion - An observational, longitudinal, prospective, long-term registry of patients with hypophosphatasia.

Brandi (PI) 2016-2020
Fondazione Cassa di Risparmio di Firenze - Establishment of stable parathyroid cellular models to study the disorders of the parathyroid glands.

Brandi (PI) 2017-2018
Shire international – Observational study on hypoparathyroidism in the Tuscany Region.

Brandi (PI) 2017-2022
Fondazione Cassa di Risparmio di Firenze- Establishment and characterization of cell cultures obtained from human musculoskeletal biopsies for the study of muscle regeneration.

Brandi (PI) 2018
The Rotary Foundation - Distretto 2071 - New possibilities for the treatment of mineralization disorders in rare diseases.

Brandi (PI) 2018-2019
Banca d'Italia - FirmoLab: development and implementation of the research activity of a specialized laboratory for the study of the cellular and molecular bases of mineralization disorders in rare bone diseases.

Brandi (co-applicant) 2018-2020
Regione Toscana - Development of an antagomir complex against human miR24-1, conjugated with magnetic nanoparticles, for molecular therapy of multiple endocrine neoplasia type 1 (DANTE).

Brandi (PI) 2018-2022
Kyowa Kirin - X-linked Hypophosphatemia Registry Protocol.

Brandi (PI) 2018-2022
Alexion – Hypophosphatasia and atypical skeletal fractures.

Brandi (PI) 2018-2022
Shire International - A Randomized, Double-blind, Placebo-controlled, Adaptive Study to Evaluate Symptom Improvement and Metabolic Control Among Adult Subjects With Symptomatic Hypoparathyroidism Treated With Recombinant Human Parathyroid Hormone[rhPTH(1-84)].

Brandi (PI) 2018-2022
Kyowa Kirin - A Phase 3b Open-label Study of the Anti-FGF23 Antibody, Burosumab (KRN23) in Adult Patients with X-linked Hypophosphatemia (XLH).

Brandi (PI) 2018-2022
Faes Farma - Effect of the administration of different Hidroferol® Soft Gelatine Capsules (calcifediol) and cholecalciferol (Dibase®) regimens on 25(OH)D levels and markers of bone remodelling in postmenopausal women with 25(OH)D deficiency. Influence of clinical and genetic factors in the osteoporotic and nonosteoporotic population.

Brandi (PI) 2019-2020
Fondazione Cassa di Risparmio di Firenze - Development of an *in vitro* bioassay system for cannabinoids.

Brandi (PI) 2019-2021
Abiogen Pharma – Effects of bisphenol A on vitamin D metabolism.

Brandi (co-applicant) 2019-2022
MIUR-PRIN - Physiopathology, Epidemiology and Genetics of primary pArathyroid hormone deficiency and reSistance: a mUlticenter italian Study (PEGASUS).


Brandi (PI) 2020-2022
Regione Toscana – The Omics Sciences Against Osteosarcoma (TOSCANO).

No Profit Experience

2006-present President and Found Raiser for Fondazione Italiana Ricerca sulle Malattie dell'Osso (F.I.R.M.O.)
(see website: www.fondazionefirmo.com)

Ai sensi del D. lgs. 196/03, art. 13, si autorizza il trattamento e la diffusione dei dati riportati nel presente C.V.

Firenze, 20 Febbraio 2020



Prof.ssa Maria Luisa Brandi